Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy

外科肿瘤学 医学 乳腺癌 肿瘤科 激素疗法 卵巢癌 内科学 激素 妇科 癌症
作者
Ruchi Patel,Elizabeth Weil,Sara Bugamelli,Emma Carroll,Kylie Steinke,Erinn Stockhausen,John D. Burfeind,Colin J. Mooney,Janet Retseck,Deepika Sriram,Jutta Deininger,Angela Halbach,Maressa Sweeney,Sailaja Kamaraju,Lubna Naaz Chaudhary,Yee Chung Cheng
出处
期刊:Breast Cancer Research [BioMed Central]
卷期号:27 (1): 147-147 被引量:6
标识
DOI:10.1186/s13058-025-01979-x
摘要

BACKGROUND: Breast cancer is the most common malignancy among females. The Tamoxifen and Exemestane Trial (TEXT) and the Suppression of Ovarian Function Trial (SOFT) were two landmark studies, which showed adjuvant therapy with the aromatase inhibitor (AI), exemestane, or tamoxifen combined with ovarian function suppression (OFS) improved disease-free survival (DFS) among premenopausal women (Pagani et al. in N Engl J Med 371(2):107-118, 2014). However, data has since emerged regarding incomplete OFS with Gonadotropin-releasing hormone (GnRH) agonists in some premenopausal patients. The SOFT Estrogen Substudy (SOFT-EST) was a prospective substudy of SOFT, which evaluated estradiol (E2) levels to determine if patients on exemestane and triptorelin experienced suboptimal ovarian function suppression. In this study, 17% of patients had an E2 level greater than 2.72 pg/mL at each time point, which was determined to be incomplete OFS. This study called into question whether E2 levels should routinely be monitored in women on GnRH agonists (Bellet et al. in J Clin Oncol 34(14):1584-1593, 2016). The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) provide recommendations to monitor E2 levels in premenopausal patients on an aromatase inhibitor (AI) due to the concern of incomplete OFS for patients receiving GnRH agonist therapy (Burstein et al. in J Clin Oncol 37(5):423-438, 2019, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2024. www.nccn.org ). The purpose of our study is to develop and implement a protocol for monitoring E2 levels at Froedtert & MCW based on the NCCN and ASCO recommendations. METHODS: This study implemented an OFS monitoring guideline in combination with a collaborative practice agreement at Froedtert & MCW. Pharmacists were responsible for ordering and monitoring E2 levels monthly on eligible patients based on a specified protocol. An E2 level ≤ 2.72 pg/mL while receiving an AI or ≤ 21 pg/mL while receiving tamoxifen in addition to a GnRH agonist injection was defined as complete OFS. E2 levels were retrospectively analyzed to evaluate if patients had incomplete OFS and if clinical management changed based on those levels. The primary outcome was proportion of patients identified per the E2 monitoring protocol that fail to achieve OFS for two consecutive levels over an 18-month period. Nominal data were compared using the chi-squared or Fisher's exact test, and continuous data using the Mann Whitney U or student's t-test, where appropriate. RESULTS: A total of 85 patients were reviewed at the time of analysis. Fifty-three patients (62.4%) achieved complete OFS (three consecutive E2 levels within goal), compared to 17 patients (20%) demonstrating incomplete OFS. Seven patients (8.2%) did not have enough consecutive levels demonstrating complete or incomplete OFS and E2 lab monitoring continues. Eight patients (9.4%) declined lab monitoring. Out of the 17 patients with incomplete OFS, 14 underwent a change in their GnRH agonist as an intervention aimed at achieving complete OFS. Among these 14 patients, 7 successfully attained OFS, 5 continued to experience incomplete OFS, and 2 opted to decline future monitoring. . More patients were chemotherapy naïve in the continued incomplete OFS group compared to those who had complete OFS after intervention (p = 0.010). CONCLUSION: Our study has shown a trend toward the need for checking E2 levels to assess for incomplete OFS and that changing GnRH agonist agent can improve rates of complete OFS for some patients. Additionally, our study has shown that chemotherapy naïve patients experience more incomplete OFS; however, further data is needed to validate these results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
芈钥发布了新的文献求助10
刚刚
1秒前
2秒前
3秒前
sssyz发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
4秒前
852的应助被zzd采纳,获得10
4秒前
wyc发布了新的文献求助10
5秒前
5秒前
5秒前
bwlldw完成签到,获得积分10
5秒前
666完成签到 ,获得积分10
5秒前
慕鳞完成签到,获得积分10
5秒前
MIO完成签到,获得积分10
6秒前
7秒前
8秒前
Owen的应助被呼噜呼噜毛儿采纳,获得10
8秒前
梁艳完成签到,获得积分10
8秒前
atishoo发布了新的文献求助10
9秒前
大个的应助被机智的师采纳,获得10
9秒前
漂亮的烙发布了新的文献求助10
10秒前
大可完成签到 ,获得积分10
10秒前
深情安青的应助被斯文的热狗采纳,获得10
10秒前
大吱吱发布了新的文献求助10
10秒前
10秒前
11秒前
11秒前
11秒前
11秒前
学术渣发布了新的文献求助10
12秒前
优美绿草完成签到,获得积分20
12秒前
黑米粥发布了新的文献求助200
12秒前
脑洞疼的应助被123采纳,获得10
12秒前
二汀完成签到,获得积分10
13秒前
康康完成签到 ,获得积分10
13秒前
13秒前
NexusExplorer的应助被SYX采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178449
求助须知:如何正确求助?哪些是违规求助? 9569267
关于积分的说明 21803160
捐赠科研通 7773332
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556833
邀请新用户注册赠送积分活动 2478436